Taylor Cottrill Erickson & Associates Inc. Makes New $423,000 Investment in Quanterix Co. (NASDAQ:QTRX)

Taylor Cottrill Erickson & Associates Inc. bought a new position in shares of Quanterix Co. (NASDAQ:QTRX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 8,505 shares of the company’s stock, valued at approximately $423,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Eaton Vance Management bought a new position in Quanterix during the first quarter worth about $25,000. FORA Capital LLC boosted its holdings in Quanterix by 326.5% during the second quarter. FORA Capital LLC now owns 1,224 shares of the company’s stock worth $72,000 after buying an additional 937 shares during the last quarter. Cutler Group LP bought a new position in Quanterix during the second quarter worth about $87,000. US Bancorp DE boosted its holdings in Quanterix by 103.1% during the second quarter. US Bancorp DE now owns 1,489 shares of the company’s stock worth $87,000 after buying an additional 756 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its holdings in Quanterix by 68.9% during the first quarter. Great West Life Assurance Co. Can now owns 1,583 shares of the company’s stock worth $92,000 after buying an additional 646 shares during the last quarter. Hedge funds and other institutional investors own 82.13% of the company’s stock.

NASDAQ:QTRX opened at $43.07 on Friday. The business’s 50-day simple moving average is $49.92 and its 200-day simple moving average is $52.31. Quanterix Co. has a fifty-two week low of $41.05 and a fifty-two week high of $92.57. The stock has a market capitalization of $1.58 billion, a PE ratio of -31.67 and a beta of 1.45.

Quanterix (NASDAQ:QTRX) last announced its earnings results on Thursday, November 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.13). Quanterix had a negative net margin of 44.63% and a negative return on equity of 11.88%. During the same period last year, the business posted $0.07 earnings per share. Equities analysts anticipate that Quanterix Co. will post -1.79 earnings per share for the current year.

Several equities analysts have recently weighed in on QTRX shares. Canaccord Genuity cut their price objective on Quanterix from $90.00 to $75.00 and set a “buy” rating on the stock in a report on Thursday, August 5th. Zacks Investment Research cut Quanterix from a “hold” rating to a “sell” rating in a report on Wednesday, November 10th.

In other Quanterix news, CEO E Kevin Hrusovsky sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 10th. The stock was sold at an average price of $55.18, for a total transaction of $275,900.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP David C. Duffy sold 1,667 shares of the business’s stock in a transaction that occurred on Wednesday, September 22nd. The stock was sold at an average price of $47.72, for a total value of $79,549.24. The disclosure for this sale can be found here. In the last three months, insiders sold 32,844 shares of company stock worth $1,731,644. 15.40% of the stock is owned by insiders.

Quanterix Company Profile

Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development.

Featured Story: How a Strangle Strategy is different from a Straddle Strategy

Institutional Ownership by Quarter for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.